Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.48 USD | +7.08% | +8.07% | -32.30% |
11/06 | Transcript : Vistagen Therapeutics, Inc., Q4 2024 Earnings Call, Jun 11, 2024 | |
11/06 | Vistagen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Business Summary
Number of employees: 40
Sales per Business
USD in Million | 2023 | Weight | 2024 | Weight | Delta |
---|---|---|---|---|---|
Central Nervous System Therapies
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | -568.10% |
Sales per region
USD in Million | 2023 | Weight | 2024 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | -568.10% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shawn Singh
CEO | Chief Executive Officer | 61 | 01/00/01 |
Cynthia Anderson
DFI | Director of Finance/CFO | 55 | 21/23/21 |
Joshua Prince
COO | Chief Operating Officer | 54 | 01/21/01 |
Ann Cunningham
BRD | Director/Board Member | 56 | 10/19/10 |
Mark McPartland
IRC | Investor Relations Contact | 58 | 04/16/04 |
Jessica Haskell
SEC | Corporate Secretary | - | 01/22/01 |
Human Resources Officer | - | 01/22/01 | |
Ross Baker
PRN | Corporate Officer/Principal | - | 01/21/01 |
Erik Berglund
LAW | General Counsel | - | 01/21/01 |
Louis Monti
PRN | Corporate Officer/Principal | - | 01/20/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jon Saxe
BRD | Director/Board Member | 88 | 01/00/01 |
Jerry Gin
BRD | Director/Board Member | 81 | 01/16/01 |
Shawn Singh
CEO | Chief Executive Officer | 61 | 01/00/01 |
Chairman | 58 | 21/21/21 | |
Ann Cunningham
BRD | Director/Board Member | 56 | 10/19/10 |
Joanne Curley
BRD | Director/Board Member | 56 | 23/21/23 |
Mary Rotunno
BRD | Director/Board Member | 64 | 06/21/06 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 27,029,731 | 26,971,854 ( 99.79 %) | 4,522 ( 0.0167 %) | 99.79 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.30% | 87.83M | |
+16.41% | 122B | |
+19.38% | 115B | |
+21.22% | 26.64B | |
-23.72% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.20% | 15.49B | |
+64.00% | 14.83B | |
+2.25% | 13.67B |
- Stock Market
- Equities
- VTGN Stock
- Company Vistagen Therapeutics, Inc.